Clinical Research

At Sanovel, we regard clinical research not merely as a regulatory requirement, but as an integral component of scientific excellence.

We continue to advance our integrated approach to clinical research through our extensive expertise and leading position in bioequivalence studies.

With deep scientific knowledge, proven experience and a strong commitment to quality, we deliver reliable, high-standard outcomes in bioequivalence studies, which form the cornerstone of generic drug development.

Through our clinical and bioequivalence studies, we contribute to scientifically demonstrating the efficacy and safety of medicines while continuing to serve as a trusted partner within the pharmaceutical industry.

Advancing Science, Creating Value For Health

Through our clinical research and bioequivalence studies, we aim to create value for human health by expanding access to high-quality treatment options that patients can use with confidence. Our clinical research activities are founded upon:

• Full compliance with national and international guidelines and regulatory requirements (TITCK, EMA, FDA and ICH),
• Commitment to ethical principles and participant safety,
• The highest standards of data quality,
• Scientific transparency and long-term sustainability.

Every study we undertake is viewed as an opportunity to generate scientific knowledge and create meaningful value for healthcare.

We are committed to advancing scientific knowledge by publishing the findings of our clinical and bioequivalence studies in internationally peer-reviewed journals. As one of the leading organizations conducting bioequivalence research in Türkiye, we actively contribute to the global scientific literature through high-quality clinical research.

Our Publications:

• • Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions– Scientific Reports, 2025 (https://doi.org/10.1038/s41598-025-04800-z)
• • Bioequivalence Study of Capsules versus Film Tablets Containing Rivaroxaban in Healthy Caucasian Subjects under Fasting and Fed Conditions– American College of Clinical Pharmacology (ACCP), 2023 https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1342
• • Bioequivalence Shown Between Two FDC of Dapagliflozin and Metformin XR Formulations in Healthy Participants under Fed and Fasting Conditions- Academia Drug Development and Pharmacotherapy (Currently undergoing the publication approval process.)